Cost-Effectiveness Analysis of4Therapeutic Schemes in the Treatment of Type 2 Diabetes / 中国药房

ABSTRACT

OBJECTIVE:To discuss the cost-effectiveness of4therapeutic schemes in the treatment of Type2diabetes.METHODS:Cost-effectiveness analyses were made on4therapeutic schemes by using pharmacoeconomical principle,which weremetformin+clipizde(Scheme A),metformin+pioglitazone(Scheme B),metformin+repaglinide(Scheme C),and met-formin+novolin30R(Scheme D).RESULTS:There was no significant difference in the total effective rate among4schemes.The cost-effectiveness ratios in Scheme A,B,C and D were2.21,3.21,2.63,and6.54,respectively.The cost-effectiveness ratios increments in Scheme B,C,and D were64.82,—6.41,and51.25as against Scheme A.CONCLUSION:Among the4schemes,Scheme A is the preferable choice.